



MDS Pharma Services Completes 100th Phase I Study with Strategic Partner Daiichi Sankyo

*U.S. Contract Research Organization and leading Japanese pharmaceutical company
extend long-term alliance to 2011*

KING OF PRUSSIA, PA, December 11, 2008 – MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, today announced the achievement of a significant milestone with the completion of 100 clinical studies for Daiichi Sankyo Pharma Development, a division of Japanese pharmaceutical company Daiichi Sankyo, Inc.

The majority of the studies were conducted at the Daiichi Sankyo Clinical Pharmacology Unit, which is located within the MDS Pharma Services early clinical facility in Neptune, N.J., and took place during the course of the companies' six-year strategic partnership, which was recently extended to 2011.

“During the past six years, MDS Pharma Services' ability to provide quality, on-time service has resulted in a mutually beneficial, long-term partnership with Daiichi Sankyo that has now seen the completion of 100 clinical studies – and counting,” said MDS Pharma Services President David Spaight. “Our unique and proven approach to building partnerships with valued clients, such as Daiichi Sankyo, is evident in the close consultative approach we've taken to our work together – one that goes far beyond tactical execution.”

Since establishing the partnership in 2002, MDS Pharma Services has conducted a wide array of complex clinical pharmacology studies for the U.S. subsidiary of Daiichi Sankyo Co. Inc., one of Japan's leading pharmaceutical companies. These include drug-drug interaction studies, Thorough QT and pivotal bioequivalence/bioavailability studies, as well as many first-in-human studies.

“Our partnership with MDS Pharma Services has been an integral element of the successful execution of our drug development strategy,” said Dr. Dan Salazar, Vice-President Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development. “The scientific, medical and operational expertise at MDS Pharma Services positions them to meet our clinical trial needs. The dedicated bed space we have at Neptune – combined with the valuable experience both companies have gained from the completion of 100 studies together – have helped to facilitate and accelerate study planning, start-up and execution. Working with MDS Pharma Services in this way has created a unique and successful model for us.”



Daiichi Sankyo and MDS Pharma Services began their working relationship six years ago with the establishment of the 40-bed Daiichi Sankyo Clinical Pharmacology Unit at the contract research organization's Neptune location. Dedicated MDS Pharma Services staff members provide support to both clinical and non-clinical activities for Daiichi Sankyo.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at www.mdsp.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

SOURCE MDS Inc.

For more information, contact:

Media: Charlene McGrady, (610) 239-7900 ext. 231, charlene.mcgrady@mdsinc.com